[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647798":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":11,"responsibleParty":25,"collaborators":11,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":29,"sex":35,"minAge":36,"maxAge":11,"enrollmentInfo":37,"targetDuration":11,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":11,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":11},{"fullName":5,"class":6},"Kardium Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Globe Pulsed Field System","EXPERIMENTAL",null,[13],"Device: Globe Pulsed Field System",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DEVICE","Ablation and atrial mapping with the Globe Pulsed Field System",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Clinical Affairs","CONTACT","+1 (604) 248 8891","Clinical.Affairs@kardium.com",{"type":26,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647798","evaluation-of-the-safety-and-effectiveness-of-the-globe-pulsed-field-system-for-treating-patients-with-symptomatic-paroxysmal-atrial-fibrillation-100647798",false,"NCT07714876","Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation","A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation - Post Approval Study","PULSAR PAS","Key Inclusion Criteria:\n\n* A diagnosis of recurrent symptomatic paroxysmal atrial fibrillation\n* Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III\n\nKey Exclusion Criteria:\n\n* Persistent or long-standing persistent atrial fibrillation (continuous atrial fibrillation that is sustained \\>12 months)\n* Atrial fibrillation secondary to a reversible cause or of non-cardiac origin\n* History of thromboembolic events within the past six months\n* Myocardial infarction (MI)\u002Fpercutaneous coronary intervention (PCI) within the last three months\n* Any cardiac surgery within the previous six months\n* Prior left atrial ablation or surgical procedure\n* Presence of any pulmonary vein stents\n* Body mass index (BMI) \\>40 kg\u002Fm\\^2\n* Left ventricular ejection fraction (LVEF) \\\u003C35%\n* Anterior-posterior left atrial (LA) diameter \\>55mm","ALL","18 Years",{"count":38,"type":39},250,"ESTIMATED","INTERVENTIONAL",[42],"NA","This study will evaluate the long-term safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal atrial fibrillation.",[45],"Paroxysmal Atrial Fibrillation","NOT_YET_RECRUITING","2026-07-17",{"date":49,"type":50},"2026-07-20","ACTUAL",{"date":52,"type":39},"2026-12",{"date":54,"type":39},"2031-12",{"name":5,"class":6}]